Jpmorgan Chase & CO Silverback Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 32,822 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,822
Previous 33,000 0.54%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024
SELL
N/A
-178 Reduced 0.54%
32,822 $0
Q2 2024

Aug 12, 2024
SELL
N/A
-17,183 Reduced 34.24%
33,000 $0
Q1 2024

May 10, 2024
BUY
N/A
15,534 Added 44.83%
50,183 $0
Q4 2023

Feb 12, 2024
BUY
N/A
369 Added 1.08%
34,649 $0
Q3 2023

Nov 14, 2023
BUY
N/A
11,746 Added 52.13%
34,280 $0
Q2 2023

Aug 11, 2023
BUY
N/A
19,612 Added 671.18%
22,534 $0
Q1 2023

May 11, 2023
BUY
N/A
350 Added 13.61%
2,922 $0
Q4 2022

Feb 13, 2023
BUY
$0.0 - $6.07 $0 - $2,798
461 Added 21.84%
2,572 $22,000
Q3 2022

Nov 14, 2022
BUY
$3.91 - $5.52 $2,400 - $3,389
614 Added 41.02%
2,111 $11,000
Q2 2022

Aug 11, 2022
SELL
$2.9 - $4.44 $35,556 - $54,438
-12,261 Reduced 89.12%
1,497 $6,000
Q1 2022

May 11, 2022
SELL
$3.51 - $6.74 $554,811 - $1.07 Million
-158,066 Reduced 91.99%
13,758 $49,000
Q4 2021

Feb 10, 2022
BUY
$6.03 - $11.67 $736,709 - $1.43 Million
122,174 Added 246.07%
171,824 $1.14 Million
Q3 2021

Nov 12, 2021
BUY
$9.98 - $35.22 $495,507 - $1.75 Million
49,650 New
49,650 $495,000

Others Institutions Holding SBTX

# of Institutions
163
Shares Held
62.7M
Call Options Held
872K
Put Options Held
589K
View Full List

About Silverback Therapeutics, Inc.

SBTX Quotes by TradingView
  • Ticker SBTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,473,800
  • Description
  • Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...
More about SBTX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email